- Home
- GLUE vs ROOT Comparison
GLUE vs ROOT Comparison
Compare GLUE & ROOT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GLUE | ROOT |
|---|---|---|
| Founded | 2019 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Property-Casualty Insurers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.3B |
| IPO Year | 2021 | 2020 |
Fundamental Metrics
Financial Performance| Metric | GLUE | ROOT |
|---|---|---|
| Price | $24.92 | $75.84 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 5 |
| Target Price | $27.00 | ★ $125.80 |
| AVG Volume (30 Days) | ★ 2.4M | 262.2K |
| Earning Date | 11-06-2025 | 02-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | 0.25 | ★ 3.34 |
| Revenue | $181,538,000.00 | ★ $1,446,800,000.00 |
| Revenue This Year | $84.02 | $29.96 |
| Revenue Next Year | N/A | $5.89 |
| P/E Ratio | $100.27 | ★ $22.69 |
| Revenue Growth | ★ 1112.27 | 38.50 |
| 52 Week Low | $3.50 | $68.08 |
| 52 Week High | $25.77 | $181.14 |
Technical Indicators
Market Signals| Indicator | GLUE | ROOT |
|---|---|---|
| Relative Strength Index (RSI) | 70.77 | 49.86 |
| Support Level | $13.69 | $68.12 |
| Resistance Level | $25.77 | $77.29 |
| Average True Range (ATR) | 1.49 | 2.63 |
| MACD | 0.81 | 0.36 |
| Stochastic Oscillator | 86.63 | 81.29 |
Price Performance
Historical ComparisonAbout GLUE Monte Rosa Therapeutics Inc.
Monte Rosa Therapeutics Inc is a biotechnology company that specializes in developing molecular glue degraders (MGDs), a class of small molecule drugs that leverage the body's natural protein destruction mechanisms to selectively degrade therapeutically-relevant proteins. Utilizing the QuEEN platform, the company employ artificial intelligence and proprietary experimental tools to identify target proteins for degradation by MGDs. With a diverse library of over 50,000 MGD molecules, their product candidate, MRT-2359, targets the translation termination factor protein GSPT1 for potential use in MYC-driven tumors. The company's focus lies in advancing its pipeline of MGDs, aiming to provide novel therapeutic modalities for various diseases.
About ROOT Root Inc.
Root Inc develops and launches a direct-to-consumer personal automobile insurance and mobile technology company. It generates revenue from the sales of auto insurance policies within the United States.